CONCORSO PUBBLICO, PER ESAMI, PER IL RECLUTAMENTO DI N. 1 UNITÀ DI PERSONALE AFFERENTE ALL'AREA DEI FUNZIONARI - SETTORE SCIENTIFICO-TECNOLOGICO, CON RAPPORTO DI LAVORO SUBORDINATO A TEMPO INDETERMINATO PRESSO L'UNIVERSITÀ DEGLI STUDI DI MILANO - DIPARTIMENTO DI SCIENZE DELLA SALUTE - CODICE 22526

La Commissione giudicatrice della selezione, nominata con Determina Direttoriale n. 6958 del 28/04/2025, composta da:

Prof.ssa Chiara Mando'	Presidente
Dott. Cristian Loretelli	Componente
Dott.ssa Paola Eugenia Zermiani	Componente
Dott. Riccardo Lavezzi	Segretario

comunica i quesiti relativi alla prova orale:

GRUPPO DI QUESITI n. 1

- Descrivere le procedure di misurazione del contenuto e della funzione mitocondriale.

Brano in inglese:

After a 2-week screening period, participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention. Lifestyle intervention included regular lifestyle counseling sessions, delivered by a dietitian or a qualified health care professional, to help the participants adhere to healthful, balanced meals, with a deficit of 500 calories per day, and at least 150 minutes of physical activity per week.

GRUPPO DI QUESITI n. 2

- Descrivere le procedure di misurazione di stress ossidativo cellulare.

Brano in inglese:

All randomly assigned participants were to undergo a planned 72-week treatment period that included a dose-escalation period of up to 20 weeks.
Tirzepatide was initiated at a dose of 2.5 mg once weekly (or matching placebo) and was increased by 2.5 mg every 4 weeks during the dose-escalation period to reach a maintenance dose of up to 15 mg once weekly by week 20. After the 72-week treatment period, participants who had been without prediabetes at randomization proceeded to a 4-week safety follow-up period; those with prediabetes at randomization continued in their original treatment group for an additional 2-year trial treatment period.

GRUPPO DI QUESITI n. 3

- Descrivere le procedure di misurazione dei processi di apoptosi.

Brano in inglese:

The coprimary end points were the percentage change in body weight from baseline to week 72 and a weight reduction of 5% or more at week 72. Key secondary end points included weight reduction of 10% or more, 15% or more, and 20% or more at week 72; the change in weight from baseline to week 20; and the change from baseline to week 72 in waist circumference, systolic blood pressure, fasting insulin and lipid levels, and the physical function score on the 36-Item Short Form Health Survey (SF-36), version 2, acute form. The

percentage change in total body-fat mass from baseline to week 72 was assessed in subgroup of 255 participants who underwent dual-energy x-ray absorptiometry.

GRUPPO DI QUESITI n. 4

- Descrivere le tecniche di valutazione al microscopio confocale.

Brano in inglese:

We calculated that a sample size of 2400 participants would provide an effective power of greater than 90% to demonstrate the superiority of tirzepatide (10 mg, 15 mg, or both) to placebo, relative to the coprimary end points, each at a two-sided significance level of 0.025. The sample-size calculation assumed at least an 11-percentage-point difference in the mean percentage weight reduction from baseline at 72 weeks for tirzepatide (10 mg, 15 mg, or both) as compared with placebo, a common standard deviation of 10%, and a dropout rate of 25%.

GRUPPO DI QUESITI n. 5

- Descrivere le tecniche di isolamento e caratterizzazione delle microvescicole.

Brano in inglese:

The coprimary end points were the percentage change in body weight from baseline to week 72 and a weight reduction of 5% or more at week 72. Key secondary end points included weight reduction of 10% or more, 15% or more, and 20% or more at week 72; the change in weight from baseline to week 20; and the change from baseline to week 72 in waist circumference, systolic blood pressure, fasting insulin and lipid levels, and the physical function score on the 36-Item Short Form Health Survey (SF-36), version 2, acute form. The percentage change in total body-fat mass from baseline to week 72 was assessed in a subgroup of 255 participants who underwent dual-energy x-ray absorptiometry.

Milano, 5 giugno 2025

La Commissione

Prof.ssa Chiara Mando' - Presidente

Dott. Cristian Loretelli - Componente

Dott.ssa Paola Eugenia Zermiani - Componente

Dott. Riccardo Lavezzi - Segretario